Cerêve Raises $38 Million to Fuel Launch of Insomnia Device in New Financing Led by KKR
January 5, 2017
Investment Will Fund Launch of
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170105005480/en/
Fifty-five million Americans have insomnia, not only experiencing
problems getting to sleep but also serious impairment in their daytime
activities. Currently, sleeping pills are the most common medical
treatment for insomnia. According to the
“We are thrilled to bring on KKR as a business partner to join our very
strong and supportive current investor group and look forward to working
together as we finalize preparations for our 2017 U.S. market launch,”
stated
As part of the transaction,
Earlier this year, Cerêve received
Cerêve will initially deploy its funding to build out its infrastructure and prepare for product launch during the second half of 2017.
For KKR, the investment is part of the firm’s health care growth equity strategy, which is focused on high-growth companies for which KKR can be a unique partner in helping reach scale.
About Cerêve
Based near
For more information, or to receive updates as Cerêve becomes available, visit www.cerevesleep.com.
About KKR
KKR is a leading global investment firm that manages investments across
multiple asset classes including private equity, energy, infrastructure,
real estate, credit and hedge funds. KKR aims to generate attractive
investment returns by following a patient and disciplined investment
approach, employing world-class people, and driving growth and value
creation at the asset level. KKR invests its own capital alongside its
partners’ capital and brings opportunities to others through its capital
markets business. References to KKR’s investments may include the
activities of its sponsored funds. For additional information about
SOURCES:
Roth T, Coulouvrat C, Hajak G, et al. Prevalence and perceived health
associated with insomnia based on DSM-IV-TR; International Statistical
Classification of Diseases and Related Health Problems, Tenth Revision;
and Research Diagnostic Criteria/International Classification of Sleep
Disorders, Second Edition criteria: results from the
Chong Y, Fryar CD, Gu Q. Prescription sleep aid use among adults:
View source version on businesswire.com: http://www.businesswire.com/news/home/20170105005480/en/
Media
Cerêve
contact@cerevesleep.com
or
KKR
media@kkr.com
Source:
Back to Press Releases
Media Contacts
Americas
Miles Radcliffe-Trenner
Telephone: +1 (212) 750-8300
Email: media@kkr.com
Investor Relations
Craig Larson
Telephone: +1 (877) 610-4910
Outside US: +1 (212) 230-9410
Facsimile: +1 (212) 750-0003
Email: Investor-Relations@kkr.com